Pharmaceuticals, Biotechnology and Life Sciences
– Systemic sclerosis (SSc) is a rare disease that impacts up to 75,000 people in the United States –
– Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung func…
Alexion will present data highlight long-term and real-world efficacy of SOLIRIS® (eculizumab) in patients living with rare neurologic complement-mediated disorders, including neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG).
After the US president’s Biden said the US Federal government would buy 100 million doses of the COVID-19 vaccine from Moderna and another 100 million from Pfizer, Moderna today confirmed that it is in discussion with the U.S. government to purchase an additional 100 million doses of the Moderna COVID-19 Vaccine for delivery in the third quarter of 2021.
Teneobio, Inc. and its affiliate TeneoThree, Inc. announced today that their investigational new drug application (IND) for TNB-585, a bispecific T-cell engaging antibody for the treatment of metastatic castrate resistant prostate cancer (mCRPC) was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration (FDA) on January 23, 2021.
Myovant Sciences and Pfizer said Monday that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination…
U.S. FDA has authorized mRNA vaccine against COVID-19 for emergency use as total of 200 million doses ordered by the U.S government to date, with an option to purchase up to an additional 300 million doses, while approximately 20 million doses will be delivered by the end of December 2020.
Moderna has received positive recommendation in support of Emergency Use Authorization of its COVID-19 vaccine candidate in USA.
Mesoblast’s COVID-19 ARDS trial was powered to achieve a primary endpoint of 43% reduction in mortality at 30 days for treatment with remestemcel-L on top of maximal care in a trial of 300 patients.
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) — VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to…
The FDA has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction